The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
|Videos|April 26, 2011
Phase II AMG 386 and Paclitaxel Combination Trial
Author(s)Beth Y. Karlan MD
Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Beth Y. Karlan MD Director at Cedars-Sinai Women's Cancer Research Institute Provides an Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Related to this article
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
4
VIR-5500 Receives FDA Fast Track Designation in mCRPC
5